Cell
Resolution Therapeutics Secures £63.5M in Series B Funding to Advance Macrophage Cell Therapy for Liver Disease
Resolution Therapeutics, Series B funding, macrophage cell therapy, liver disease, regenerative medicine, biopharmaceuticals
J&J and Legend’s Carvykti Demonstrates Significant Survival Benefit in Earlier-Line Multiple Myeloma Treatment
Carvykti, multiple myeloma, CAR-T therapy, Johnson & Johnson, Legend Biotech, CARTITUDE-4, survival benefit, second-line treatment
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta
GC Therapeutics Secures $75 Million Funding for Revolutionary Stem Cell Technology
GC Therapeutics, George Church, stem cell startup, biotech funding, transcription factor screening
Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer
Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.
WCLC24: Merck & Daiichi Sankyo’s ADC Shows Promising Results in Small Cell Lung Cancer
WCLC24, Merck & Co., Daiichi Sankyo, ADC (Antibody Drug Conjugate), SCLC (Small Cell Lung Cancer), Ifinatamab Deruxtecan, DXd ADC Technology
Promising Phase 2 Results for Ifinatamab Deruxtecan in Small Cell Lung Cancer
Ifinatamab Deruxtecan, Small Cell Lung Cancer, Phase 2 Trial, ADC Technology, Daiichi Sankyo, Merck
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market